NCT06078306View on ClinicalTrials.gov

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2025

Conditions
B Acute Lymphoblastic LeukemiaPh-Negative ALLHigh Risk Acute Lymphoblastic Leukemia
Interventions
DRUG

Azacitidine Injection

Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection

DRUG

Venetoclax

Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral

DRUG

CD19CD22 CAR-T

After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion

Trial Locations (1)

215000

RECRUITING

Xiaowen Tang, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER